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Introduction
Bladder cancer is the fifth most common cancer in the world and the most costly cancer to treat on a per-patient basis due to required clinical surveillance and multiple therapeutic interventions [1] . Muscle-invasive bladder cancer (MIBC) is a highly aggressive flavor of the disease with a 5-yr survival probability of 50% [2] . Despite efforts in refining surgical techniques and optimizing systemic therapy, the prognosis has remained unchanged for more than 20 yrs [3] . Clinical improvement can be ascribed cisplatin-based neoadjuvant chemotherapy (NAC), which offers an overall survival benefit of 5-6% [4] and is currently standard of care in MIBC [5] . However, only 40% of patients demonstrate a major response to NAC and adverse treatment effects and delay in surgery, potentially harm 60%. Therefore, secondline treatment options for MIBC are currently in great demand [6] . Although 60% of patients with metastatic MIBC demonstrate an objective response to cisplatin-based chemotherapy, this response is rarely durable, and most of these patients succumb to disease [7] . Atezolizumab has recently become the first Food and Drug Administrationapproved agent for second-line treatment of metastatic bladder cancer [8] , but there remains a great need for additional agents in all states of MIBC.
Glycosaminoglycans (GAGs) are carbohydrate modifications attached to proteins in the cell membrane. Changes in expression and composition of GAGs have been reported in bladder cancer over the past 3 decades [9] [10] [11] . Chondroitin sulfate (CS) is a major cancer-associated GAG that also has a key role in malaria pathogenesis [12] . The malaria parasite Plasmodium falciparum has evolved a protein, called VAR2CSA that mediates attachment of infected erythrocytes to a distinct type of CS in the placental syncytium [13] . CS chains comprise repeated disaccharide units, made up of glucoronic acid and N-acetylgalactosamine (GalNAc) residues. CS chains are highly heterogeneous showing variations in both chain length and disaccharide modifications. Placental-type CS is mainly sulfated on carbon-4 of the GalNAc hexose, and this particular modification is required for exclusive sequestration of VAR2CSA-positive erythrocytes in the placenta [14] . Placenta and cancer share obvious phenotypic features such as highly proliferating cells, the ability to invade adjacent tissue, and promoting angiogenesis [15] . In the placenta, these features are partly facilitated by CS, and many tumors re-express placentaltype CS as an oncofetal GAG [16] . Therefore, recombinant malarial VAR2CSA (rVAR2) proteins can be conveniently utilized to detect oncofetal chondroitin sulfate (ofCS) in human cancer [16, 17] . Finally, rVAR2 conjugated with the hemiasterlin toxin analog KT886 derived from the marine sponge Hemiasterella minor (rVAR2 drug conjugate [VDC] 886), showed antitumor activity in non-Hodgkin's lymphoma, prostate cancer, and metastatic breast cancer with no adverse treatment effects in non-pregnant mice [16] .
We noticed that several cancer-associated proteins can be modified with an ofCS chain, including CD44 [16] , syndican-1 (SDC1) [18] , and chondroitin sulfate proteoglycan 4 (CSPG4) [19] , and that CD44 and SDC1 have previously been described as candidate biomarkers in bladder cancer [20] [21] [22] [23] [24] [25] . Accordingly, we hypothesized that human MIBC might display ofCS chains that could be exploited for rVAR2-based targeted therapy. In particular, we aimed to interrogate the ofCS expression landscape in cisplatinresistant MIBC with the intention of developing an additional line treatment option for this disease state.
2.
Patients and methods
Bladder cancer patient cohorts
Bladder tumor tissue was collected at three institutions (University of Bern, Switzerland; Vancouver General Hospital, Canada; and University
Hospital of Southampton, UK) from patients receiving at least three cycles of cisplatin-based NAC prior to radical cystectomy with pelvic lymph node dissection (Supplementary Table 1 ). Tissue was harvested from prechemotherapy transurethral resection of bladder tumor (TURBT) specimens in all patients and from postchemotherapy radical cystectomy specimens in patients with residual MIBC (ypT). The Bern cohort was used as the discovery cohort, and the Vancouver and Southampton cohorts were amalgamated as the validation cohort.
A complete and detailed description of the patients and methods used in this study can be found in the Supplementary Information.
Results
To analyze the ofCS expression in bladder cancer pre-and post-treatment with cisplatin-based chemotherapy, we performed immunohistochemical (IHC) analysis of two 
independent cohorts of matched primary chemotherapynaïve and cisplatin-resistant bladder tumors using rVAR2 as the ofCS detection reagent (Fig. 1A and B, and Supplementary Fig. 1A-E) . The ofCS expression was absent in urothelium of the adjacent normal bladder (Fig. 1A, left) and was highly restricted to the bladder tumors (Fig. 1A,  right) . To differentiate ofCS expression between tumor environment and cancer cell compartments, we performed IHC analysis of an epithelial marker, E-cadherin, and a mesenchymal marker, vimentin (Fig. 1A) . The pre-chemotherapy bladder tumors were sampled by transurethral resection (TURBT) and the matched cisplatin-resistant tumors after NAC were sampled from subsequent radical cystectomy specimens (Fig. 1B) . The discovery cohort comprised more advanced tumors from a single institution as compared with the validation cohort combined from two institutions (Supplementary Table 1 ). Overall, high ofCS expression was seen in approximately 92% (n = 110/120) of chemotherapy-naïve bladder tumors in both cohorts. Among these, 17% (n = 8/47) of the tumors in the discovery cohort ( Table 2 ). Aggregated, these data indicate that ofCS is upregulated in cisplatin-resistant bladder cancer, and this event may be associated with a poor outcome. Several proteoglycans can carry ofCS GAG modifications [16] . To search for ofCS-modified proteoglycans in bladder cancer, we analyzed gene expression data of known CSmodified proteoglycans [16, 28] in two independent bladder cancer cohorts. In both datasets, luminal-type tumors were enriched for SDC1, SDC4, and APLP2, while more basal tumors were enriched for a number of genes including CD44 and CSPG4 ( Fig. 2A , and Supplementary Fig. 2A-E) . SDC1, CSPG4, and CD44 have been widely associated with multiple types of cancer [16, 18, 19] , and CD44 and SDC1 have previously been suggested as candidate biomarkers in bladder cancer [20] [21] [22] [23] [24] [25] . Indeed, protein expression of CD44 ( these data suggest that CD44, SDC1, and CSPG4 are expressed in human bladder cancer and associated with ofCS modifications. We next analyzed a panel of seven bladder cancer cell lines derived from MIBC patients for ofCS expression by flow cytometry using rVAR2 as the ofCS detection reagent. All MIBC cell lines analyzed expressed ofCS as detected by rVAR2 in a concentration-and CS-dependent manner (Fig. 3A) . This was supported by sensitivity to the ofCStargeting VDC886 drug conjugate [16] in the low-nanomolar IC 50 concentration range (Fig. 3B) . Interestingly, four out of seven cell lines expressed CSPG4, seven out of seven expressed splice variants of CD44, and five out of seven expressed SDC1 (Fig. 3C ), but this expression pattern was not obviously related to VDC886 sensitivity. This might indicate that not all of the selected proteoglycans (CD44, SDC1, and CSPG4) are modified with ofCS in the individual cell lines and/or that additional proteoglycans contribute to the ofCS presentation. To investigate this further, we analyzed whether or not CD44, SDC1, and CSPG4 were modified with ofCS in UM-UC13 cells. The ofCS-modified proteins were purified from cell lysates using immobilized rVAR2. The resulting fractions were treated with chondroitinase ABC to reduce the CSPGs down to their core protein component. In this analysis, a shift in gel mobility toward the predicted protein size on SDS-PAGE upon chondroitinase ABC treatment would imply CS substitution. Surprisingly, while CD44, SDC1, and CSPG4 were expressed in UM-UC13 cells, only SDC1 and CSPG4 produced a shift in molecular weight after chondroitin treatment (Fig. 3D) . Chondroitinase ABC treatment did not reduce the size of SDC1 to its predicted core protein size, but merely produced an intermediary sized protein. This is in line with the heparan sulfate substitution status of SDC1, a GAG that will not be digested with chondroitinase ABC. These data indicate that SDC1 and CSPG4, but not CD44, are ofCS modified in UM-UC13 cells. To validate this result, we treated UM-UC13 cells with validated siRNAs targeting CD44, SDC1, and CSPG4, and assayed for binding to rVAR2 as an indication of ofCS expression. While the CD44 siRNA had no effect on rVAR2 binding, SDC1 and CSPG4 siRNAs reduced rVAR2 binding to UM-UC13 cells by 50% and 20%, respectively (Fig. 3E) . This corroborates the biochemical analysis showing that SDC1 and CSPG4, but not CD44, are ofCS modified in UM-UC13 cells, reflecting that ofCS modification of eligible proteins is not mandatory and likely a dynamic event.
To assess the expression of ofCS-modified proteoglycans in cells treated with cisplatin in vivo we inoculated UM-UC13 cells into the bladder wall of nude mice with ultrasound guidance (Supplementary Fig. 3A and B) [26, 27] . As the UM-UC13 tumors developed, the mice were subjected to cisplatin treatment and resistant tumors were allowed to recover. To analyze the ofCS modification status of proteoglycans in UM-UC13 tumors and to potentially identify novel proteoglycans, we purified ofCS-associated proteoglycans from ex vivo cells and analyzed those by mass spectrometry. This analysis identified eight ofCS-modified 
EURURO-7303; No. of Pages 9 proteoglycans including SDC1 and CSPG4 (Supplementary Table 3 ). Similar to the in vitro cell line study, this analysis showed that CD44 was not modified with ofCS in UM-UC13 cells, and that ofCS modification of SDC1 and CSPG4 was retained in vivo. Proximity-ligation assay analysis of ofCS chains and CD44, SDC1, and CSPG4 confirmed the mass spectrometry result (Supplementary Fig. 3C ), but surprisingly, CD44 was also in proximity to ofCS. This suggests that while CD44 is not itself modified with ofCS in UM-UC13 cells, it is indeed expressed in close proximity to ofCS-modified proteoglycans. Capitalizing on our findings that human cisplatinresistant MIBC upregulates ofCS (Fig. 1A-F) and that MIBC cells are sensitive to VDC886 in vitro (Fig. 3B) , we next tested whether VDC886 had efficacy against cisplatin-resistant MIBC in vivo. Again, UM-UC13 cells were inoculated into the bladder wall of nude mice with ultrasound guidance ( Supplementary Fig. 3A and B) and tumor growth was subsequently monitored using ultrasound over a 40-60 days period ( Supplementary Fig. 4A ). As the UM-UC13 tumors developed, the mice were subjected to repeating cycles of cisplatin treatment and the resultant tumors were passaged through six generations of mice (G1-G6) creating highly stable cisplatin-resistant xenografts (Fig. 4A) . Importantly, the ex vivo tumor cells retained their rVAR2 binding in a concentration-and CS-dependent manner (Fig. 4B) . They also retained the same rVAR2 internalization capacity as the parental line, G0 (Fig. 4C) . Notably, the completely cisplatinresistant G6 and cisplatin-sensitive G0 cells showed equal sensitivity to VDC886 ex vivo ( Fig. 4D and Supplementary  Fig. 4B) .
Next, mice with established G6-initiated cisplatinresistant tumors were randomized into four groups and treated bi-weekly (four treatments in total) with vehicle, rVAR2, KT886, or VDC886 (Fig. 4E) in combination with cisplatin. The G6 cisplatin-resistant tumors expressed SDC1, Fig. 4C ). Remarkably, VDC886 treatment strongly retarded growth of cisplatinresistant tumors (Fig. 4F and G) and significantly prolonged survival of the mice (Fig. 4H) . Importantly, a clinicopathological examination of VDC886-treated mice demonstrated no organ toxicity (Supplementary Fig. 4D ) and the weight of the mice was stable in all groups (Supplementary Fig. 4E ). In the VDC886-treated group, one mouse had complete response, one mouse presented with significant tumor regression ( Supplementary Fig. 4F ), and four mice had stable tumor growth inhibition without progression during the experiment, with viable tumor cells in histology. In summary, our work demonstrates that ofCS-modified proteoglycans can provide therapeutic access to cisplatinresistant MIBC.
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Discussion
We have tested an unconventional approach for treating cisplatin-resistant MIBC based on the evolutionarily refined parasite-host anchor protein VAR2CSA derived from the malaria parasite P. falciparum. We found that ofCS was 
present at high levels in cisplatin-resistant MIBC, promoting ofCS as a potential access point for targeted therapy. Supporting this notion, VDC886 was able to suppress the growth of cisplatin-resistant MIBC. High ofCS expression was associated with advanced tumor stage, cisplatin resistance, and poor overall survival of MIBC patients. These associations were more robust in the discovery cohort, which contained more advanced disease and a longer follow-up. In the validation cohort, presentation of ofCS was not prognostic. While this suggests that high ofCS may only relate to survival in more advanced MIBC, this association requires further investigation. Several different proteoglycans can be modified with ofCS chains [16] . As a result, intratumoral heterogeneity in proteoglycan expression does not necessarily translate into varying levels of ofCS modifications. CD44 has previously been shown to carry ofCS chains in melanoma [16, 29, 30] . We found that CD44 mRNA and protein expression correlated with high ofCS presentation in MIBC, but biochemical interrogation showed that CD44 was not modified with ofCS, at least not in UM-UC13 cells. Contrary to CD44, SDC1 and CSPG4 were modified in UM-UC13 cells and correlated with ofCS expression in primary tumors. Mass spectrometry of rVAR2-purified proteoglycans identified another six ofCS-modified candidates. It is likely that additional proteoglycans contribute to ofCS presentation in MIBC.
The most important finding of our study was the increased cellular ofCS expression in cisplatin-resistant MIBC when compared with paired chemotherapy-naïve MIBC. These findings suggest that targeting ofCS with VDC886 provides an attractive approach, particularly in cisplatin-resistant MIBC. The first-generation VDC compound VDC886 comprises the DBL1X-ID2a domains of the malarial VAR2CSA protein loaded with an average of three KT886 hemiasterlin toxin analogs derived from the marine sponge H. minor [16] . VDC886 eliminated all MIBC cell lines in the low-nanomolar IC 50 concentration range. As all the MIBC cell lines investigated express high levels of ofCS, the small differences in IC 50 are most likely due to differences in internalization kinetics. In an animal model of cisplatinresistant MIBC, VDC886 was able to efficiently target established cisplatin-resistant tumors and rescue the mice from tumor-associated morbidity and death. The completely cisplatin-resistant G6 and cisplatin-sensitive G0 cells isolated from mice showed equal sensitivity to VDC886 ex vivo. This is likely due to high baseline levels of ofCS in MIBC cell lines and suggests that the ofCS modification is a passenger, rather than a driver, of cisplatin resistance. Nevertheless, ofCS GAG modifications constitute a therapeutic access point in cisplatin-resistant MIBC.
Conclusions
We have found an oncofetal GAG antigen in cisplatinresistant MIBC that can be targeted by a malarial host-cell anchor protein armed with hemiasterlin compounds. This discovery potentially offers a new treatment paradigm for human MIBC patients not responding to cisplatin. Other: None. 
